Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)

Detalles Bibliográficos
Autores principales: Metro, Giulio, Bonaiti, Angelo, Birocchi, Ilaria, Marasciulo, Francesca, Ubaldi, Martina, Metelli, Niccolò, Minotti, Vincenzo, Addeo, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096286/
https://www.ncbi.nlm.nih.gov/pubmed/35572898
http://dx.doi.org/10.21037/jtd-22-98

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096286/
https://www.ncbi.nlm.nih.gov/pubmed/35572898
http://dx.doi.org/10.21037/jtd-22-98

Ejemplares similares